Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of venetoclax plus azacitidine after allogeneic stem cell transplant in acute myeloid leukemia
MOH_2019-12-02_008495Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax and azacitidine in acute myeloid leukemia (AML) (3 arms), sponsored by AbbVie Inc. Started Nov 2019; status: completed.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2019-12-02_008495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-02_008495.